Continuous erythropoietin receptor activator (Mircera) for renal anemia.
Continuous erythropoietin receptor activator (Mircera) for renal anemia.
复制标题
连续促红细胞生成素受体激活剂（Mircera）用于治疗肾性贫血。
DOI：
--
复制
发表时间：
2008
期刊：
影响因子：
--
通讯作者：
L. McGahan
中科院分区：
文献类型：
--
作者：
L. McGahan
(1)连续促红细胞生成素受体激活剂（CERA）是第三代促红细胞生成素刺激剂（ESA）。CERA用于纠正肾功能衰竭患者的贫血和维持血红蛋白水平。CERA每两周一次（纠正贫血）或每月一次（维持血红蛋白水平）。这比其他需要更频繁管理的esa具有潜在的优势。(2)两项涉及erythropoietin-naïve患者的3期试验发现，每两周使用一次CERA纠正肾性贫血与每周最多使用三次其他esa的结果没有差异。四项三期试验报告，每月一次CERA的透析患者维持稳定的血红蛋白水平与其他每周施用三次的药物相当。需要进一步的临床试验来检查其他重要结果，如死亡率和主要不良反应。(3) CERA最常见的不良反应为高血压、腹泻、头痛和上呼吸道感染。与其他esa相比，CERA出现程序性低血压（给药期间血压低）、胃肠道出血和心动过速的风险更高。(4)延长时间间隔给予CERA可简化贫血管理，减轻患者负担，减少卫生保健人员用于治疗的时间。
(1) Continuous erythropoietin receptor activator (CERA) is a third-generation erythropoiesis stimulating agent (ESA). CERA is used to correct anemia and maintain hemoglobin levels in patients with renal (kidney) failure. CERA is administered either once every two weeks (to correct anemia) or once per month (to maintain hemoglobin levels). This offers a potential advantage over other ESAs that require more frequent administration. (2) Two phase 3 trials involving erythropoietin-naïve patients found no difference between correcting renal anemia with CERA once every two weeks compared to results with other ESAs that were administered up to three times weekly. Four phase 3 trials reported that maintenance of stable hemoglobin levels in dialysis patients with once-monthly CERA was comparable to other agents that were administered up to three times weekly. Further clinical trials are needed to examine other important outcomes, such as mortality and major adverse effects. (3) The most common adverse effects with CERA were hypertension, diarrhea, headache, and upper respiratory tract infection. There was a higher risk of procedural hypotension (low blood pressure during administration), gastrointestinal hemorrhage, and tachycardia with CERA compared to other ESAs. (4) Administration of CERA at extended intervals may simplify anemia management, reduce the burden on patients, and decrease health care staff time spent administering the treatment.